Univariate relationships between AM and selected clinical outcomes
| . | GVH . | HVG . | ||||
|---|---|---|---|---|---|---|
| Outcome . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Class I AM* | ||||||
| Relapse | 0.917 | 0.688-1.223 | NS | 1.042 | 0.788-1.377 | NS |
| RFS | 1.178 | 0.909-1.526 | NS | 1.363 | 1.056-1.760 | .018 |
| Neutrophil engraftment | — | — | — | 0.870 | 0.743-1.019 | .085 |
| Platelet engraftment | — | — | — | 0.871 | 0.743-1.021 | .088 |
| Class II AM† | ||||||
| Relapse | 0.720 | 0.524-0.990 | .043 | 0.785 | 0.571-1.079 | .136 |
| RFS | 0.819 | 0.633-1.061 | .130 | 0.922 | 0.715-1.188 | NS |
| Neutrophil engraftment | — | — | — | 0.876 | 0.684-1.120 | NS |
| Platelet engraftment | — | — | — | 0.734 | 0.575-0.938 | .013 |
| Total AM‡ | ||||||
| Relapse | 0.848 | 0.696-1.033 | NS | 0.914 | 0.749-1.116 | NS |
| RFS | 0.998 | 0.849-1.175 | NS | 1.131 | 0.948-1.349 | .173 |
| Neutrophil engraftment | — | — | — | 0.896 | 0.786-1.022 | .101 |
| Platelet engraftment | — | — | — | 0.832 | 0.738-0.937 | .002 |
| . | GVH . | HVG . | ||||
|---|---|---|---|---|---|---|
| Outcome . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Class I AM* | ||||||
| Relapse | 0.917 | 0.688-1.223 | NS | 1.042 | 0.788-1.377 | NS |
| RFS | 1.178 | 0.909-1.526 | NS | 1.363 | 1.056-1.760 | .018 |
| Neutrophil engraftment | — | — | — | 0.870 | 0.743-1.019 | .085 |
| Platelet engraftment | — | — | — | 0.871 | 0.743-1.021 | .088 |
| Class II AM† | ||||||
| Relapse | 0.720 | 0.524-0.990 | .043 | 0.785 | 0.571-1.079 | .136 |
| RFS | 0.819 | 0.633-1.061 | .130 | 0.922 | 0.715-1.188 | NS |
| Neutrophil engraftment | — | — | — | 0.876 | 0.684-1.120 | NS |
| Platelet engraftment | — | — | — | 0.734 | 0.575-0.938 | .013 |
| Total AM‡ | ||||||
| Relapse | 0.848 | 0.696-1.033 | NS | 0.914 | 0.749-1.116 | NS |
| RFS | 0.998 | 0.849-1.175 | NS | 1.131 | 0.948-1.349 | .173 |
| Neutrophil engraftment | — | — | — | 0.896 | 0.786-1.022 | .101 |
| Platelet engraftment | — | — | — | 0.832 | 0.738-0.937 | .002 |